GUIZHOU SANLI PHARMACEUTICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.43 CNY | +0.78% |
|
+5.11% | -18.27% |
| Sales 2024 * | 2.09B 288M 24.05B | Sales 2025 * | 2.57B 355M 29.58B | Capitalization | 6.32B 873M 72.77B |
|---|---|---|---|---|---|
| Net income 2024 * | 333M 45.96M 3.83B | Net income 2025 * | 417M 57.55M 4.8B | EV / Sales 2024 * | 3.03 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.46 x |
| P/E ratio 2024 * |
18.9
x | P/E ratio 2025 * |
15.1
x | Employees | 1,557 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 40.36% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.78% | ||
| 1 week | +5.11% | ||
| Current month | -3.74% | ||
| 1 month | -2.83% | ||
| 3 months | -8.54% | ||
| 6 months | -16.37% | ||
| Current year | -18.27% |
1 week
14.88
15.60
1 month
14.0416.21
Current year
11.9220.06
1 year
11.9220.65
3 years
10.7421.28
5 years
8.8244.10
10 years
8.8244.10
| Managers | Title | Age | Since |
|---|---|---|---|
Hai Zhang
CEO | Chief Executive Officer | 39 | 01/08/01 |
Hong Yu Zhang
DFI | Director of Finance/CFO | 61 | 01/13/01 |
Qian Fan Zhang
BRD | Director/Board Member | 39 | 01/14/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shi Gui Chen
BRD | Director/Board Member | 61 | 12/22/12 |
Qiang Wang
BRD | Director/Board Member | 54 | 12/22/12 |
Hai Zhang
CEO | Chief Executive Officer | 39 | 01/08/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 15.43 | +0.78% | 4,667,000 |
| 25/24/25 | 15.31 | +0.92% | 4,014,320 |
| 24/24/24 | 15.17 | -0.39% | 3,608,900 |
| 23/24/23 | 15.23 | +1.67% | 5,770,083 |
| 22/24/22 | 14.98 | +2.04% | 5,415,763 |
End-of-day quote Shanghai S.E., April 26, 2024
More quotes
Guizhou Sanli Pharmaceutical Co Ltd is a company mainly engaged in the research and development, production and sales of Chinese patent medicines. The Company's product lines cover various areas, including pediatrics, respiratory systems, cardio-cerebrovascular and gastroenterology. Its main products are Kaihoujian spray (Pediatric Use), Kaihoujian spray and Qiangli Gastrodia Elata Eucommia capsules. The Kaihoujian spray (Pediatric Use) and Kaihoujian spray are used for the treatment of respiratory and oral diseases, and the Qiangli Gastrodia Elata Eucommia capsule is used for the treatment of cardiovascular and cerebrovascular diseases. The Company mainly sells its products through specialized academic marketing.
Sector
Pharmaceuticals
Calendar
30/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
15.43
CNY
Average target price
19.84
CNY
Spread / Average Target
+28.58%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -18.27% | 873M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 603439 Stock
